MDMA in PTSD
February 13, 2019 DOI: 10.64239/pi-qt0303
Summary
AI-generated from the abstractMDMA, used alongside psychotherapy in two sessions one month apart plus 18 hours of therapy without the drug, showed a very strong effect size at a full dose compared to a small-dose active control. Although not intended for routine clinical use, the results were striking. Phase III clinical trials are expected to follow.
Study at a glance
| Characteristics | Randomized controlled trial |
|---|---|
| Interventions | MDMA Psychotherapy |
| Duration | Two therapy sessions 1 month apart, 18 hours of psychotherapy without MDMA |
| Key finding | MDMA at full dose exhibited a very strong effect size relative to a small-dose active control when used adjunctively with psychotherapy. |
Abstract
As just one of several psychotropics being examined for potential adjunctive use with psychotherapy, MDMA exhibited a very strong effect size at full dose relative to a small-dose “active control." It was used in two therapy sessions, 1 month apart, in addition to 18 hours of psychotherapy without MDMA–all of which was manual driven. Although MDMA is not going to be used routinely with our patients, it’s interesting to see that this work is being performed, and the results were striking. Watch for phase III clinical trials to follow based on this work.